Megace ES

See also: Generic Megace

Megace ES is a brand name of megestrol, approved by the FDA in the following formulation(s):

MEGACE ES (megestrol acetate - suspension; oral)

• 
  Manufacturer: PAR PHARM
  
  Approval date: July 5, 2005
  
  Strength(s): 125MG/ML ^[RLD]

Has a generic version of Megace ES been approved?

No. There is currently no therapeutically equivalent version of Megace ES available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Megace ES. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Nanoparticulate dispersions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
  Patent 6,592,903
  Issued: July 15, 2003
  Inventor(s): Niels P.; Ryde & Stephen B.; Ruddy
  Assignee(s): Elan Pharma International Ltd.
  Disclosed are solid dose nanoparticulate compositions comprising a poorly soluble active agent, at least one polymeric surface stabilizer, and dioctyl sodium sulfosuccinate (DOSS). The solid dose compositions exhibit superior redispersibility of the nanoparticulate composition upon administration to a mammal, such as a human or animal. The invention also describes methods of making and using such compositions.
  
  Patent expiration dates:
  
  
  • September 21, 2020
    
    ✓ 
    Drug product
  
  



• 
  Nanoparticulate megestrol formulations
  Patent 7,101,576
  Issued: September 5, 2006
  Inventor(s): Hovey; Douglas & Pruitt; John & Ryde; Tuula
  Assignee(s): Elan Pharma International Limited
  The present invention is directed to nanoparticulate compositions comprising megestrol. The megestrol particles of the composition have an effective average particle size of less than about 2000 nm.
  
  Patent expiration dates:
  
  
  • April 22, 2024
    
    ✓ 
    Patent use: TREATMENT OF ANOREXIA, CACHEXIA, OR AN UNEXPLAINED, SIGNIFICANT WEIGHT LOSS IN PATIENTS WITH A DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)
  
  

See also...

• Megace ES Consumer Information (Drugs.com)
• Megace ES Suspension Consumer Information (Wolters Kluwer)
• Megace ES Consumer Information (Cerner Multum)
• Megestrol Consumer Information (Wolters Kluwer)
• Megestrol Suspension Consumer Information (Wolters Kluwer)
• Megestrol Consumer Information (Cerner Multum)
• Megestrol Acetate AHFS DI Monographs (ASHP)